NASDAQ · Financial Statements

Bio-Techne Corp (TECH) Revenue, Earnings & Financial Statements

$72.63 NASDAQ: TECH Market Cap $11.41B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Bio-Techne Corp most recently reported annual revenue of $1.2B, net profit of $182.0M. Revenue grew at an average annual rate of 5.5% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Bio-Techne Corp: Revenue rose from $563.0M in 2017 to $1.2B in 2026, a change of +115.8% over 9 years; net profit was positive in all 10 reported years; operating margin moved from 21.6% to 20.7%, a shift of -0.9 percentage points; the most recent year shows net profit of $182.0M.

Income Statement — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Revenue$563.0M$643.0M$714.0M$739.0M$931.0M$1.1B$1.1B$1.2B$1.2B$1.2B
Operating Expenses$441.0M$507.0M$588.0M$581.0M$694.0M$809.0M$838.0M$952.0M$1.1B$963.0M
Operating Profit$122.0M$136.0M$126.0M$157.0M$237.0M$297.0M$299.0M$207.0M$102.0M$252.0M
Operating Margin21.6%21.2%17.6%21.3%25.5%26.8%26.3%17.8%8.4%20.7%
Other Income−$9.0M−$10.0M−$35.0M$119.0M−$89.0M$5.0M$40.0M−$21.0M−$4.0M−$11.0M
Interest$7.0M$10.0M$22.0M$19.0M$14.0M$11.0M$11.0M$16.0M$9.0M$5.0M
Depreciation$60.0M$64.0M$78.0M$83.0M$88.0M$101.0M$107.0M$112.0M$110.0M$97.0M
Profit Before Tax$113.0M$126.0M$112.0M$276.0M$148.0M$301.0M$339.0M$186.0M$98.0M$241.0M
Tax rate (%)31.7%-0.5%14.2%17.1%5.8%12.7%15.7%9.5%25.4%24.4%
Net Profit$77.0M$125.0M$96.0M$229.0M$140.0M$272.0M$285.0M$168.0M$73.0M$182.0M
EPS$0.52$0.82$0.62$1.45$0.87$1.66$1.76$1.05$0.46$1.16

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$273.0M$303.0M$306.0M$289.0M$297.0M$316.0M$317.0M$287.0M$296.0M$311.0M$321.0M$300.0M
Operating Expenses$235.0M$236.0M$260.0M$249.0M$250.0M$277.0M$341.0M$239.0M$241.0M$236.0M$247.0M$263.0M
Operating Profit$38.0M$67.0M$46.0M$40.0M$47.0M$39.0M−$24.0M$48.0M$54.0M$75.0M$74.0M$37.0M
Operating Margin13.9%22.1%15.0%13.8%16.0%12.2%-7.5%16.6%18.4%24.2%23.1%12.2%
Interest$4.0M$4.0M$3.0M$2.0M$2.0M$2.0M$2.0M$3.0M$2.0M$3.0M$3.0M$2.0M
Profit Before Tax$33.0M$61.0M$42.0M$40.0M$43.0M$38.0M−$23.0M$48.0M$51.0M$71.0M$71.0M$35.0M
Tax rate (%)17.7%19.7%2.6%16.4%18.6%41.0%22.7%20.4%25.2%28.3%22.7%18.4%
Net Profit$27.0M$49.0M$41.0M$34.0M$35.0M$23.0M−$18.0M$38.0M$38.0M$51.0M$55.0M$28.0M
EPS$0.17$0.31$0.25$0.21$0.22$0.14−$0.11$0.24$0.24$0.32$0.36$0.18

Over the 10 years reported for Bio-Techne Corp, borrowings decreased from $350.0M in 2017 to $289.0M in 2026, cash stood at $265.0M in the latest year, shareholders' equity was $2.0M, current assets covered current liabilities 4.54 times.

Balance Sheet — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Total Assets$1.6B$1.6B$1.9B$2.0B$2.3B$2.3B$2.6B$2.7B$2.6B$2.6B
Current Assets$345.0M$398.0M$413.0M$521.0M$511.0M$606.0M$621.0M$617.0M$608.0M$744.0M
Cash$92.0M$122.0M$101.0M$147.0M$199.0M$173.0M$181.0M$152.0M$162.0M$265.0M
Inventory$60.0M$86.0M$91.0M$103.0M$117.0M$141.0M$172.0M$180.0M$189.0M$196.0M
Receivables$117.0M$120.0M$137.0M$123.0M$145.0M$195.0M$218.0M$241.0M$207.0M$217.0M
Fixed Assets$135.0M$145.0M$154.0M$248.0M$282.0M$289.0M$325.0M$342.0M$319.0M$299.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$106.0M$62.0M−$25.0M$124.0M$32.0M$74.0M$280.0M$243.0M$251.0M$246.0M
Other Assets$579.0M$598.0M$733.0M$728.0M$843.0M$822.0M$873.0M$973.0M$981.0M$975.0M
Total Liabilities$606.0M$514.0M$719.0M$646.0M$692.0M$594.0M$672.0M$635.0M$639.0M$479.0M
Current Liabilities$135.0M$79.0M$102.0M$107.0M$152.0M$176.0M$129.0M$159.0M$176.0M$164.0M
Borrowings$350.0M$339.0M$505.0M$434.0M$421.0M$326.0M$455.0M$420.0M$444.0M$289.0M
Other Liabilities$256.0M$175.0M$214.0M$213.0M$271.0M$268.0M$217.0M$215.0M$195.0M$189.0M
Equity$0$0$0$0$0$2.0M$2.0M$2.0M$2.0M$2.0M
Reserves$951.0M$1.1B$1.2B$1.4B$1.6B$1.7B$2.0B$2.1B$1.9B$2.1B

For Bio-Techne Corp, operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $263.0M; free cash flow was positive in 10 of 10 years; financing activities used $54.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2017201820192020202120222023202420252026
Operating Cash Flow$143.0M$170.0M$182.0M$205.0M$352.0M$325.0M$254.0M$299.0M$288.0M$292.0M
Investing Cash Flow−$358.0M−$60.0M−$384.0M−$25.0M−$288.0M−$142.0M−$304.0M−$266.0M−$66.0M−$47.0M
Financing Cash Flow−$16.0M−$47.0M$16.0M$14.0M$3.0M−$107.0M−$21.0M−$41.0M−$231.0M−$54.0M
Net Cash Flow$27.0M$30.0M−$21.0M$46.0M$52.0M−$27.0M$8.0M−$29.0M$10.0M$103.0M
Free Cash Flow$128.0M$149.0M$156.0M$153.0M$308.0M$280.0M$216.0M$236.0M$257.0M$263.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.55
EV / EBITDA34.59
FCF Yield2.69%
Quick Ratio1.74
Interest Coverage51.89
Return 1Y24.59%
Return 3Y20.81%
Return 5Y-39.94%

Bio-Techne Corp (TECH) financials — frequently asked questions

What is Bio-Techne Corp's annual revenue?

Bio-Techne Corp (TECH) reported annual revenue of $1.2B in its most recent fiscal year.

What is Bio-Techne Corp's net profit?

Bio-Techne Corp (TECH) reported net profit of $182.0M in its most recent fiscal year.

What is TECH EV/EBITDA?

Bio-Techne Corp's enterprise value to EBITDA (EV/EBITDA) ratio is 34.59.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
TECH Overview TECH Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.